Despite appropriate antibiotic therapy, the risk of mortality in neonatal sepsis still remains high. We conducted a systematic review to comprehensively evaluate different adjuvant therapies in neonatal sepsis in a network meta-analysis.
METHODS:
We included randomized controlled trials (RCTs) and quasi-RCTs that evaluated adjuvant therapies in neonatal sepsis. Neonates of all gestational and postnatal ages, who were diagnosed with sepsis based on blood culture or sepsis screen were included. We searched MEDLINE, CENTRAL, EMBASE and CINAHL until 12th April 2021 and reference lists. Data extraction and risk of bias assessment were performed in duplicate. A network meta-analysis with bayesian random-effects model was used for data synthesis. Certainty of evidence (CoE) was assessed using GRADE.
RESULTS:
We included 45 studies involving 6,566 neonates. Moderate CoE showed IVIG [Relative Risk (RR); 95% Credible Interval (CrI): 1.00; (0.67–1.53)] as an adjunctive therapy probably does not reduce all-cause mortality before discharge, compared to standard care. Melatonin [0.12 (0–0.08)] and granulocyte transfusion [0.39 (0.19–0.76)] may reduce mortality before discharge, but CoE is very low. The evidence is also very uncertain regarding other adjunctive therapies to reduce mortality before discharge. Pentoxifylline may decrease the duration of hospital stay [Mean difference; 95% CrI: –7.48 days (–14.50–0.37)], but CoE is very low.
CONCLUSION:
Given the biological plausibility for possible efficacy of these adjuvant therapies and that the CoE from the available trials is very low to low except for IVIG, we need large adequately powered RCTs to evaluate these therapies in sepsis in neonates.
FleischmannC, ReichertF, CassiniA, HornerR, HarderT, MarkwartR, et al. Global incidence and mortality of neonatal sepsis: A systematic review and meta-analysis. Arch Dis Child. 2021;106(8):745–752.
2.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators.. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, -A systematic analysis for the global burden of disease study. Lancet. 2018;392:1789–1858.
3.
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex- Specific mortality for 282 causes of death in 195 countries and territories, -A systematic analysis for the global burden of disease study. Lancet. 2018;392:1736–188.
4.
Alliance for Maternal and Newborn Health Improvement (AMANHI) mortality study group. Population-based rates, timing, and causes of maternal deaths, stillbirths, and neonatal deaths in south Asia and sub-Saharan Africa: A multi-country prospective cohort study. Lancet Glob Health. 1297;6(12):1308.
GlaserMA, HughesLM, JnahA, NewberryD. Neonatal sepsis: A Review of pathophysiology and current management strategies. Adv Neonatal Care. 2021;21(1):49–60.
7.
CarrR, ModiN, DoréC. G-CSF and GM-CSF for treating orpreventing neonatal infections. Cochrane Database Syst Rev. 2003;2003(3):CD003066.
8.
PammiM, BrocklehurstP. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev. 2011;2011(10):CD003956.
9.
PammiM, HaqueKN. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev. 2015;(3):CD004205.
10.
OhlssonA, LacyJB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2020;1(1):CD001239.
11.
TangZ, WeiZ, WenF, WuY. Efficacy of zinc supplementation for neonatal sepsis: A systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2019;32(7):1213–1218.
12.
LiY, YangS, WangG, LiuM, ZhangZ, LiuH, et al. Effects of immunotherapy on mortality in neonates with suspected or proven sepsis: A systematic review and network meta-analysis. BMC Pediatr. 2019;19(1):270.
13.
AbiramalathaT, RamaswamyV, BandyopadhyayT, PullattayilA. Adjuvant therapies in neonatal sepsis to reduce mortality - A systematic review and network meta-analysis. Prospero. 2021;CRD42021247092. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD092.
14.
HuttonB, SalantiG, CaldwellDM, ChaimaniA, SchmidtCH, CameronC, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
15.
OuzzaniM, HammadyH, FedorowiczZ, ElmagarmidA. Rayyan —a web and mobile app for systematic reviews. Systematic Reviews. 2016;5:210.
16.
SterneJAC, SavovićJ, PageMJ, ElbersRG, BlencoweNS, BoutronI, et al. RoB A revised tool for assessing risk of bias inrandomised trials. BMJ.l. 2019;366:4898.
17.
ShimSR, KimSJ, LeeJ, RuckerG. Network meta-analysis: Application and practice using R software. Epidemiol Health. 2019;41:e2019013.
18.
BéliveauA, BoyneDJ, SlaterJ, BrennerD, AroraP. BUGSnet: AnR package to facilitate the conduct and reporting of Bayesiannetwork Meta-analyses. BMC Med Res Methodol. 2019;19(1):196.
19.
BrooksS, GelmanA. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7(4):434–455.
20.
DiasS, WeltonNJ, CaldwellDM, AdesAE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7-8):932–944.
21.
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2017. URL https://www.R-project.org/.
22.
MbuagbawL, RochwergB, JaeschkeR, Heel-AndshellD, AlhazzaniW, ThabaneL, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6(1):79.
23.
PuhanMA, SchünemannHJ, MuradMH, LiT, Brignardello-PetersenR, SinghJA, et al. GRADE Working GrouA GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
24.
AcunasBA, PeakmanM, LiossisG, DaviesET, BakoleasB, CostalosC, et al. Effect of fresh frozen plasma and gammaglobulin on humoral immunity in neonatal sepsis. Arch Dis Child Fetal Neonatal. 1994;70(3):F182–F187.
25.
AdelM, AwadHA, Abdel-NaimAB, Al-AziziMM. Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates. J Clin Pharm Ther. 2010;35(3):257–265.
26.
AhmadA, LaboradaG, BusselJ, NesinM. Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants. Pediatr Infect Dis J. 2002;21(11):1061–1065.
27.
AhmedSS, ChowdhuryM, HoqueMM, BegumD, AhmedA. Role of intravenous immunoglobulin (IVIG) as an adjuvant in the treatment of neonatal sepsis in preterm babies. J Bangladesh Coll Phys Surg. 2006;24(3):97–104.
28.
AkdagA, DilmenU, HaqueK, DilliD, ErdeveO, GoekmenT. Role of pentoxifylline and/or IgM-enriched intravenous immunoglobulin in the management of neonatal sepsis. Am J Perinatol. 2014;31(10):905–912.
29.
AktasD, DemirelB, GürsoyT, OvalıF. A randomized case-controlled study of recombinant human granulocyte colony stimulating factor for the treatment of sepsis in preterm neutropenic infants. Pediatr Neonatol. 2015;56(3):171–175.
30.
AliW, AhmedP, BhatMA, MushtaqS. Pentoxifylline in treatment of sepsis of premature infants. JK-Practitioner. 2006;13(4):204–207.
31.
AradhyaAS, SundaramV, KumarP, GanapathySM, JainA, RawatA. Double volume exchange transfusion in severe neonatal sepsis. Indian J Pediatr. 2016;83(2):107–113.
32.
BaleyJE, StorkEK, WarkentinPI, ShurinSB. Buffy coat transfusions in neutropenic neonates with presumed sepsis: A prospective, randomized trial. Pediatrics. 1987;80(5):712–720.
33.
BanupriyaN, BhatBV, BenetBD, CatherineC, SridharMG, ParijaSC. Short term oral zinc supplementation among babies with neonatal sepsis for reducing mortality and improving outcome - A double-blind randomized controlled trial. Indian J Pediatr. 2018;85(1):5–9.
34.
Bedford RussellAR, EmmersonAJ, WilkinsonN, ChantT, SweetDG, HallidayHL, et al. A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed.-F. 2001;84(3):F172–F176.
35.
BilginK, YaramisA, HaspolatK, TasMA, GünbeyS, DermanO. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics. 2001;107(1):36–41.
36.
BorjianyazdiL, FroomandiM, Noori ShadkamM, HashemiA, FallahR. The effect of granulocyte colony stimulating factor administration on preterm infant with neutropenia and clinical sepsis: A randomized clinical trial. Iran J Ped Hematol Oncol. 2013;3(2):64–68.
37.
CairoMS, RuckerR, BennettsGA, HicksD, WorcesterC, AmlieR, et al. Improved survival of newborns receiving leukocyte transfusions for sepsis. Pediatrics. 1984;74(5):887–892.
38.
CairoMS, WorcesterC, RuckerR, BennettsGA, AmlieR, PerkinR, et al. Role of circulating complement and polymorphonuclear leukocyte transfusion in treatment and outcome in critically ill neonates with sepsis. J Pediatr. 1987;110(6):935–941.
39.
CairoMS, WorcesterCC, RuckerRW, HantenS, AmlieRN, SenderL, et al. Randomized trial of granulocyte transfusions versus intravenousimmune globulin therapy for neonatal neutropenia and sepsis. JPediatr. 1992;120(2 Pt 1):281–285.
40.
ChaudhuriJ, MitraS, MukhopadhyayD, ChakrabortyS, ChatterjeeS. Granulocyte colony-stimulating factor for preterms with sepsis and neutropenia: A randomized controlled trial. J Clin Neonatol. 2012;1(4):202–206.
41.
ChristensenRD, BrownMS, HallDC, LassiterHA, HillHR. Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis. J Pediatr. 1991;118(4 Pt 1):606–614.
42.
ChristensenRD, RothsteinG, AnstallHB, BybeeB. Granulocyte transfusions in neonates with bacterial infection, neutropenia, and depletion of mature marrow neutrophils. Pediatrics. 1982;70(1):1–6.
43.
Drossou-AgakidouV, Kanakoudi-TsakalidouF, SarafidisK, TaparkouA, TzimouliV, TsandaliH, et al. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial. Eur J Pediatr. 1998;157(7):583–588.
44.
Drossou-AgakidouV, Kanakoudi-TsakalidouF, SarafidisK, TzimouliV, TaparkouA, KremenopoulosG, et al. In vivo effect of rhGM-CSF And rhG-CSF on monocyte HLA-DR expression of septic neonates. Cytokine. 2002;18(5):260–265.
45.
El-GanzouryMM, El-FarrashRA, SaadAA, MohamedAG, El-SherbiniIG. In vivo effect of recombinant human granulocyte colony-stimulating factor on neutrophilic expression of CD11b in septic neonates: A randomized controlled trial. Pediatr Hematol Oncol. 2012;29(3):272–284.
46.
El-KabbanyZA, El-FarghaliOG, KhafagySM, ShaabanHA, OsmanHHA, MetwallyMH. Melatonin as an adjuvant therapy in preterm infants with neonatal sepsis, randomized trial. Egypt Pediatric Association Gaz. 2020;68:2.
47.
ElfarargyMS, Al-AshmawyG, Abu-RishaS, KhattabH. Zinc supplementation in preterm neonates with late-onset sepsis: Is it beneficial? Am J Perinatol. 2020.
48.
GathwalaG, WaliaM, BalaH, SinghS. Recombinant human granulocyte colony-stimulating factor in preterm neonates with sepsis and relative neutropenia: A randomized, single-blind, non-placebo-controlled trial. J Trop Pediatr. 2012;58(1):12–18.
49.
GillanER, ChristensenRD, SuenY, EllisR, van de VenC, CairoMS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: Significant induction of peripheral and bone marrow neutrophilia. Blood. 1994;84(5):1427–1433.
50.
HaqueKN, RemoC, BahakimH. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin Exp Immunol. 1995;101(2):328–333.
51.
HaqueKN, ZaidiMH, BahakimH. IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am J Dis Child. 1988;142(12):1293–1296.
52.
INIS Collaborative Group, BrocklehurstP, FarrellB, KingA, JuszczakE, DarlowB, HaqueK, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365(13):1201–1211.
53.
JindalSV, GohilJR, NikhileshwarA. Efficacy of IgM-rich immunoglobin for treating bacterial sepsis in very-low-birth-weight preterm neonates. Perinatology. 2020;20(4):114–119.
54.
KücüködükS, SezerT, YildiranA, AlbayrakD. Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis. Scand J Infect Dis. 2002;34(12):893–897.
55.
LauterbachR, PawlikD, KowalczykD, KsycínskiW, HelwichE, ZembalaM. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo-controlled, double-blind trial. Crit Care Med. 1999;27(4):807–814.
56.
MathurNB, SubramanianBK, SharmaVK, PuriRK. Exchange transfusion in neutropenic septicemic neonates: Effect on granulocyte functions. Acta Paediatr. 1993;82(11):939–943.
57.
MehtaK, BhattaNK, MajhiS, ShrivastavaMK, SinghRR. Oral zinc supplementation for reducing mortality in probable neonatal sepsis: A double-blind randomized placebo controlled trial. Indian Pediatr. 2013;50(4):390–393.
58.
MirzaA. ReddyUN. NaseemA. KhurramSA. A study to evaluate the role of intravenous immunoglobulin (IVIG) as an adjuvant in the management of neonatal sepsis in preterm babies. Int J Med Res Health Sci. 2017;6(3):107–113.
59.
MiuraE, ProcianoyRS, BittarC, MiuraCS, MiuraMS, MelloC, et al. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics. 2001;107(1):30–35.
60.
SadanaS, MathurNB, ThakurA. Exchange transfusion in septic neonates with sclerema: Effect on immunoglobulin and complement levels. Indian Pediatr. 1997;34(1):20–25.
61.
SaeidiR, AkhavanH, TavakkolafshariJ, Shapouri-MoghaddamA. Clinical and biochemical effects of recombinant human granulocyte colony-stimulating factor on the prognosis of preterm infants with early onset neonatal sepsis. Arch Pediatr Infect Dis. 2019;7(1):e67807.
62.
SaeidiR, FarhatAS, MohammadzadehA, GholamiM. Role of immunotherapy (IVIG) in the treatment of neonatal sepsis. Iran J Neonat. 2011;2(2):22–25.
63.
SchiblerKR, OsborneKA, LeungLY, LeTV, BakerSI, ThompsonDD. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics. 1998;102(1 Pt 1):6–13.
64.
SelimK, HüseyinC, IbrahimKH, HasanBU, KazimU, HüseyinK. Effect of pentoxifylline on tumor necrosis factor-alpha and interleukin-6 levels in neonatal sepsis. Med J Malaysia. 2004;59(3):391–394.
65.
ShabaanAE, NasefN, ShoumanB, NourI, MesbahA, Abdel-HadyH. Pentoxifylline therapy for late-onset sepsis in preterm infants: A randomized controlled trial. Pediatr Infect Dis J. 2015;34(6):e143–e148.
66.
ShenoiA, NageshNK, MaiyaPP, BhatSR, Subba RaoSD. Multicenter randomized placebo-controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatr. 1999;36(11):1113–1118.
67.
WeismanLE, AnthonyBF, HemmingVG, FischerGW. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates. J Pediatr. 1993;122(6):929–937.
68.
WeismanLE, StollBJ, KueserTJ, RubioTT, FrankCG, HeimanHS, et al. Intravenous immune globulin therapy for early-onset sepsis in premature neonates. J Pediatr. 1992;121:434–443.
69.
PoggiC, DaniC. Sepsis and oxidative stress in the newborn: From pathogenesis to novel therapeutic targets. Oxid Med Cell Longev. 2018;2018:9390140.
70.
SanchezA, CalpenaAC, ClaresB. Evaluating the oxidative stress in inflammation: Role of melatonin. Int J Mol Sci. 2015;16(8):16981–17004.
71.
HendersonR, KimS, LeeE. Use of melatonin as adjunctive therapy in neonatal sepsis: A systematic review and meta-analysis. Complement Ther Med. 2018;39:131–136.
72.
HarrisE, SchulzkeSM, PatoleSK. Pentoxifylline in preterm neonates: A systematic review. Paediatr Drugs. 2010;12(5):301–311.
KrebsNF, MillerLV, HambidgeKM. Zinc deficiency in infants and children: A review of its complex and synergistic interactions. Paediatr Int Child Health. 2014;34(4):279–288.
75.
MathiasS, BalachanderB, BoscoA, BrittoC, RaoS. The effect of exchange transfusion on mortality in neonatal sepsis: A meta-analysis. Eur J Pediatr. 2021. doi: 10.1007/s00431-021-04194-w. Epub ahead of print.
